Therapeutic Asset Ratings

396 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Carboplatin Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Cetuximab Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
CIS-DIAMMINEDICHLOROPLATINUM II Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Cyclophosphamide Biliary Tract Neoplasms	Eli Lilly and Company	P1/2	CC (47)
Epirubicin Biliary Tract Neoplasms	Eli Lilly and Company	P1/2	CC (47)
EXEMESTANE Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
FULVESTRANT Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Imlunestrant Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Letrozole Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
LEUPROLIDE Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Metformin Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Olomorasib Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Palbociclib Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Pembrolizumab Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Ribociclib Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
TAMOXIFEN Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Tersolisib Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
Zoladex Solid Tumors, Adult	Eli Lilly and Company	P1/2	CC (47)
ly6249492 Obesity Disorder	Eli Lilly and Company	P2	CC (46)
BICARBONATE ION Obesity Disorder	Eli Lilly and Company	P1	CC (46)
ly3849891 Metabolic Dysfunction-Associated Steatohepatitis	Eli Lilly and Company	P1	CC (46)
ly3849891 Metabolic Dysfunction-Associated Steatotic Liver Disease	Eli Lilly and Company	P1	CC (46)
Cetuximab Endometrial Cancer	Eli Lilly and Company	P1/2	CC (45)
Olomorasib Endometrial Cancer	Eli Lilly and Company	P1/2	CC (45)
Olomorasib Pancreatic Neoplasm	Eli Lilly and Company	P1/2	CC (45)

Showing 226 to 250 of 396 assets

PreviousPage 10 of 16Next